elranatamab

Home
Ligands
elranatamab

GtoPdb Ligand ID: 12889

Synonyms: elranatamab-bcmm | Elrexfio® | PF-06863135 | PF06863135

elranatamab is an approved drug (FDA (2023))

Comment: Elranatamab (PF-06863135) is a TNFRSF17(BCMA)/CD3e bispecific monoclonal antibody. It was designed to promote T cell-mediated anti-myeloma activity by simultaneously engaging these two protein targets on B and T cells [1,3].

References
1. Grosicki S, Bednarczyk M, Kociszewska K. (2023) Elranatamab: a new promising BispAb in multiple myeloma treatment. Expert Rev Anticancer Ther, 23 (8): 775-782. [PMID:37434334]
2. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C et al.. (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med, 29 (9): 2259-2267. [PMID:37582952]
3. Yoneyama T, Kim MS, Piatkov K, Wang H, Zhu AZX. (2022) Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma. PLoS Comput Biol, 18 (7): e1009715. [PMID:35839267]

References

1. Grosicki S, Bednarczyk M, Kociszewska K. (2023)
Elranatamab: a new promising BispAb in multiple myeloma treatment.
Expert Rev Anticancer Ther, 23 (8): 775-782. [PMID:37434334]

2. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C et al.. (2023)
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Nat Med, 29 (9): 2259-2267. [PMID:37582952]

3. Yoneyama T, Kim MS, Piatkov K, Wang H, Zhu AZX. (2022)
Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.
PLoS Comput Biol, 18 (7): e1009715. [PMID:35839267]